REGENXBIO (RGNX) CEO Simpson Curran granted RSUs and stock options

Rhea-AI Filing Summary

REGENXBIO Inc. reported that Chief Executive Officer and director Simpson Curran received new equity awards on January 6, 2026. The filing shows a grant of 144,864 shares of common stock underlying a time-based restricted stock unit award at $0.00 per share, with 25% of the shares vesting on each of January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030 while continuous service is maintained. After this grant, Curran directly beneficially owned 342,467 shares of common stock. The filing also reports an option grant for 233,651 stock options with an exercise price of $14.18 per share, expiring on January 6, 2036. Twenty‑five percent of these options vest after 12 months of continuous service with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simpson Curran

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		144,864(1)	A	$0.00	342,467	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$14.18	01/06/2026		A		233,651		(2)	01/06/2036	Common Stock	233,651	$0.00	233,651	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.

2. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REGENXBIO (RGNX) report for Simpson Curran?

REGENXBIO reported that Chief Executive Officer and director Simpson Curran received grants of common stock RSUs and stock options on January 6, 2026, both recorded at a transaction price of $0.00 per share.

How many REGENXBIO (RGNX) shares were granted to Simpson Curran as RSUs?

The filing shows a grant of 144,864 shares of common stock underlying a time-based restricted stock unit award, subject to multi-year vesting conditions tied to continuous service.

What is the vesting schedule for Simpson Curran’s RSUs at REGENXBIO (RGNX)?

For the 144,864-share RSU award, 25% of the shares vest on each of January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030, so long as Curran continues providing service to the company.

What stock options were granted to Simpson Curran by REGENXBIO (RGNX)?

Simpson Curran received 233,651 stock options (Right to buy) with an exercise price of $14.18 per share, covering 233,651 shares of common stock and expiring on January 6, 2036.

How do Simpson Curran’s REGENXBIO stock options vest?

The options vest 25% after 12 months of continuous service with the company, with the remaining options vesting in equal monthly installments over the 36 months following January 6, 2027, subject to continued service.

How many REGENXBIO (RGNX) common shares does Simpson Curran own after these grants?

Following the reported RSU transaction, Simpson Curran directly beneficially owned 342,467 shares of common stock, according to the Form 4.